SM101 In systemic lupus erythematosus patients with or without a history of lupus nephritis

ISRCTN ISRCTN84672048
DOI https://doi.org/10.1186/ISRCTN84672048
Secondary identifying numbers SM101-201-sle-10
Submission date
30/06/2011
Registration date
25/08/2011
Last edited
14/12/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
In autoimmune diseases such as systemic lupus erythematosus (SLE), the immune system has lost the ability to discriminate between body-own ('self') and foreign proteins. In consequence, antibodies are generated to attack 'self'-proteins and form immune complexes which continuously activate the immune system through binding to specific immune cells in the body. As a result, the activated immune system can lead to severe organ damage, including the kidney. This study investigates a new treatment for preventing and/ or ameliorating SLE in patients with or without a history of lupus nephritis ((prolonged inflammation of kidneys). Previous investigations in SLE animal studies suggest that the drug SM101 competes with the immune complex binding and has the potential to prevent organ damage caused by the activated immune system. The aim of this study is to investigate the safety and efficacy of SM101 in the treatment of SLE patients with or without a history of lupus nephritis and a SELENA-SLEDAI score of ≥ 6.

Who can participate?
SLE patients with or without a history of lupus nephritis and a SELENA-SLEDAI score of ≥ 6.

What does the study involve?
The study includes 10 visits for non-pharmacokinetic (PK) patients and 13 visits for PK patients. There is a 3 weeks screening period, a 4 weeks treatment and a 5 months follow-up period.

What are the possible benefits and risks of participating?
Previous studies suggest that SM101 appears to be generally well tolerated and safe. However, some patients may experience some adverse reactions which have not been reported so far. The side effects may be a minor inconvenience or could be severe. Patients will be watched closely for any side effects, and the drug will be stopped if serious side effects develop.

Where is the study run from?
Thirty clinical trial sites for the SMILE study are located in Australia, Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain and UK.

When is the study starting and how long is it expected to run for?
The first enrolment of patients is planned for August 2011 with a recruitment period of 14 months until October 2012.

Who is funding the study?
SuppreMol GmbH (Germany)

Who is the main contact?
Sascha Tillmanns, Medical Director, SuppreMol GmbH
tillmanns@suppremol.com

Contact information

Mr Sascha Tillmanns
Scientific

SuppreMol GmbH
Am Klopferspitz 19
Martinsried/Munich
82152
Germany

Email tillmanns@suppremol.com

Study information

Study designPhase IIa 2:2:1 randomised double-blind placebo-controlled parallel group multi-centre proof-of-concept clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titlePhase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis
Study acronymSMILE
Study hypothesisThe human soluble Fcγ receptor SM101 competes with the binding of systemic lupus erythematosus (SLE)-specific immune complexes to effector cells and therefore interrupts the immunological cascade leading to inflammation and organ damage.
Ethics approval(s)Approval pending as of 30/06/2011
ConditionSystemic lupus erythematosus patients with or without a history of lupus nephritis
InterventionThree treatment arms, two interventions groups and a placebo in parallel fashion:
1. Intervention group 1: 6 mg/kg/week SM101 for 4 weeks
2. Intervention group 2: 12 mg/kg/week SM101 for 4 weeks
3. Placebo
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)SM101
Primary outcome measureIncidence of adverse events (AEs) during the study period according to Common Terminology Criteria for Adverse Events (CTCAE)
Secondary outcome measures1. Physical examination (screening)
2. Vital signs (screening, treatment, follow-up)
3. Body temperature (screening, treatment, follow-up)
4. Body weight (screening, treatment)
5. Electrocardiogram (ECG) (screening, treatment, follow-up)
6. Safety laboratory assessments (screening, treatment, follow-up)
7. Anti-drug antibody (ADA) (treatment, follow-up)
8. AE recording (continuously)
9. Overall and renal disease score assessments, proteinuria, urine sediment, glomerular filtration rate (GFR), biological markers, anti-double-stranded DNA (dsDNA), anti-C1q, C3, C4, urinary neutrophil gelatinase-associated lipocalin (uNGAL) (continuously)
10. Use of rescue medication (all during screening, treatment, follow-up)
Overall study start date01/08/2011
Overall study end date01/07/2013

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants50 patients
Participant inclusion criteria1. Patient has provided written informed consent prior to any study-related procedure
2. Male or female adult patients aged 18 years or older
3. Diagnosis of SLE meeting at least four revised main classification criteria of the American College of Rheumatology (ACR) with or without a history of glomerulonephritis
4. Clinically active patients with a SLE Disease Activity Index (SELENA-SLEDAI) score of ≥ 6
5. Patients with a current serological active status (anti-dsDNA or C3)
6. Concurrent maintenance immunosuppressant SLE treatment (if any) with prednisone alone or in combination with either azathioprine or mycophenolate mofetil
7. Adequate liver function
Participant exclusion criteria1. Patient is intended to receive immunosuppressive SLE treatment other than listed in the inclusion criteria
2. Patients with proteinuria > 3.5 g/day at baseline or glomerular filtration rate (GFR) < 60 mL/min/1.73 m2
3. Patients with active SLE neurological disorders
4. Patients with an acute British Isles Lupus Assessment Group (BILAG) score defined as >= 1 BILAG A score or >= 2 BILAG B scores
5. History of class VI glomerulonephritis
6. Patients with non-lupus related renal disease such as microthrombotic disease associated with antiphospholipid syndrome
7. Patients with other acute infections
8. Patient received any B cell depleting therapy
Recruitment start date01/08/2011
Recruitment end date01/10/2012

Locations

Countries of recruitment

  • Australia
  • Belgium
  • Czech Republic
  • France
  • Germany
  • Italy
  • Poland
  • Spain
  • United Kingdom

Study participating centre

SuppreMol GmbH
Martinsried/Munich
82152
Germany

Sponsor information

SuppreMol GmbH (Germany)
Industry

Am Klopferspitz 19
Martinsried/München
82152
Germany

Email tillmanns@suppremol.com
ROR logo "ROR" https://ror.org/05jgtkc28

Funders

Funder type

Industry

SuppreMol GmbH (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

14/12/2017: No publications found, verifying study status with principal investigator.